Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629444 | 0.84 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL1905118 | 0.81 | FABP5 (0.44) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL5966653 | 0.81 | FABP5 (0.39) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL7443725 | 0.80 | ALDH1A1 (0.39) | KMT2A | |
| SCHEMBL7443719 | 0.80 | ALDH1A1 (0.39) | KMT2A | |
| SCHEMBL25303011 | 0.78 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL3821937 | 0.78 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL1885672 | 0.78 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL19668361 | 0.78 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL3821607 | 0.77 | FABP5 (0.41) | FABP5FABP7KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025041103-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-02-27 | — | — | WO | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| CN-111117812-B | Environment-friendly sterilization composition and preparation method thereof | 上海江笙生物科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-111117812-A | Environment-friendly sterilization composition and preparation method thereof | 上海江笙生物科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2008140782-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1948678-A1 | COMPOUNDS FOR ENZYME INHIBITION | Proteolix, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2427/4885FABP7 2559/4885KMT2A 2735/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2537/4885FABP7 2103/4885KMT2A 1052/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | FABP5 2465/4885FABP7 4354/4885KMT2A 1865/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2253/4885FABP7 2379/4885KMT2A 2325/4885 |
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | FOLH1, KLK3, PSMA2 | FABP5 447/4885FABP7 347/4885KMT2A 2923/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | FABP5 4377/4885FABP7 3731/4885KMT2A 3318/4885 |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | FABP5 882/4885FABP7 1499/4885KMT2A 1279/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2171/4885FABP7 2391/4885KMT2A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.